Nanobiotix

NBTX · NASDAQ · Healthcare / Biotechnology

30.66USD-1.59 (-4.95%)

Price History

Full chart

Market Stats

Previous Close32.25

Open31.50

Day Range30.32 – 32.35

52-Week Range14.78 – 57.14

Volume93.11K

Market Cap1.70B

P/E (TTM)0.00

Forward P/E42.37

EPS-1.24

Dividend Yield0.00%

Beta0.57

50-Day Avg38.79

200-Day Avg33.15

About

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Laurent Levy Ph.D.
Employees100
Headquarters60 rue de Wattignies, Paris, France, 75012, USA
Websitehttps://www.nanobiotix.com

Leadership

Dr. Laurent Levy Ph.D.Co-Founder, President of the Executive Board & CEO · b. 1973
Mr. Bart Van RhijnChief Financial & Business Officer and Member of Executive Board · b. 1974
Ms. Anne-Juliette Hermant M.A.Chief People Officer & Member of Executive Board · b. 1974
Dr. Louis Kayitalire M.D.Chief Medical Officer & Member of Executive Board · b. 1959
Mr. Earl J. Bergey Ph.d.Co-Founder · b. 1955
Mr. Brandon OwensVP of Strategic Marketing & Corporate Communication
Ms. Margaret GalluzziVP & Global Head of Clinical Operations
Dr. Leonard A. Farber M.D.Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board
Ms. Anne-Sophie LariviereChief Product Innovation & Delivery Officer

Financials

Income Statement

Currency: EUR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	1.36M	970.61K	1.60M	2.77M	4.02M	5.42M	3.72M	3.48M	2.54M	2.33M	2.65M	4.78M	36.21M	-7.19M	29.64M
Growth (%)	-	-28.65%	+64.38%	+73.67%	+44.91%	+35.03%	-31.35%	-6.53%	-26.96%	-8.50%	+13.85%	+80.43%	+658.12%	-119.86%	+512.28%
Cost of Revenue	-	-	-	-	359.61K	436.31K	345.59K	-	-	-	-	985.00K	-	-	-
Gross Profit	1.36M	970.61K	1.60M	2.77M	4.02M	5.42M	3.72M	3.48M	2.54M	2.33M	2.65M	4.78M	36.21M	-7.19M	29.64M
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Expense	6.59M	6.12M	9.77M	12.39M	21.16M	27.28M	28.99M	33.55M	49.32M	38.75M	55.23M	51.48M	62.99M	61.20M	40.46M
Operating Income	-5.23M	-5.15M	-8.18M	-9.62M	-17.14M	-21.85M	-25.27M	-30.07M	-46.78M	-36.43M	-52.58M	-46.70M	-26.78M	-68.39M	-10.82M
Operating Margin	-384.27%	-530.89%	-512.67%	-347.18%	-426.92%	-403.10%	-678.86%	-864.24%	-1840.97%	-1566.80%	-1986.36%	-977.85%	-73.96%	951.21%	-36.49%
EBITDA	-5.02M	-5.01M	-7.95M	-9.31M	-16.69M	-21.37M	-24.81M	-29.45M	-45.01M	-34.86M	-45.60M	-44.22M	-23.69M	-67.67M	-12.07M
EBITDA Margin	-368.90%	-515.79%	-498.00%	-336.08%	-415.56%	-394.20%	-666.63%	-846.45%	-1771.43%	-1499.44%	-1722.89%	-925.82%	-65.42%	941.11%	-40.71%
Net Income	-5.25M	-5.33M	-8.14M	-9.56M	-17.00M	-21.88M	-26.14M	-30.34M	-50.91M	-33.59M	-47.00M	-57.04M	-39.70M	-68.13M	-23.96M
Net Income Margin	-385.69%	-549.23%	-510.50%	-344.90%	-423.46%	-403.58%	-702.39%	-872.23%	-2003.74%	-1444.73%	-1775.71%	-1194.33%	-109.64%	947.59%	-80.83%
R&D	5.21M	4.31M	6.03M	8.08M	13.90M	16.92M	17.73M	20.89M	30.41M	24.33M	30.38M	32.64M	38.40M	40.54M	23.11M
R&D as % of Total Revenue	383.20%	444.26%	377.68%	291.46%	346.23%	312.00%	476.44%	600.55%	1196.81%	1046.45%	1147.64%	683.33%	106.04%	-563.85%	77.98%
Interest Expense	30.77K	77.00K	24.57K	55.73K	59.52K	102.20K	108.37K	847.00K	4.79M	333.00K	699.49K	5.84M	7.98M	8.09M	10.39M
Interest Expense % of Total Revenue	2.26%	7.93%	1.54%	2.01%	1.48%	1.89%	2.91%	24.35%	188.63%	14.32%	26.43%	122.22%	22.04%	-112.46%	35.07%

Balance Sheet

Currency: EUR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	2.91M	14.02M	7.44M	37.05M	26.42M	30.40M	57.47M	46.20M	56.20M	134.03M	101.77M	59.77M	93.90M	67.42M	67.76M
Total Liabilities	1.99M	3.33M	4.26M	6.74M	10.81M	13.00M	13.54M	31.95M	58.11M	63.56M	74.98M	86.81M	95.74M	133.12M	152.24M
Total Equity	925.53K	10.70M	3.18M	30.32M	15.61M	17.40M	43.92M	14.24M	-1.91M	70.47M	26.79M	-27.05M	-1.84M	-65.70M	-84.48M
Cash	898.52K	12.36M	5.00M	32.99M	17.00M	21.06M	47.21M	36.20M	35.09M	119.15M	83.92M	41.39M	75.28M	49.74M	52.75M
Total Debt	822.21K	1.43M	1.11M	2.32M	4.60M	5.67M	4.73M	20.52M	44.53M	48.98M	46.02M	53.17M	50.56M	50.90M	95.32M
Net Debt	-76.31K	-10.93M	-3.90M	-30.66M	-12.40M	-15.39M	-42.48M	-15.68M	9.43M	-70.17M	-37.90M	11.78M	-24.72M	1.17M	42.57M

Cash Flow

Currency: EUR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-4.87M	-3.76M	-6.83M	-8.56M	-16.82M	-18.28M	-20.95M	-25.98M	-41.17M	-27.54M	-29.87M	-37.10M	-12.48M	-19.55M	-33.42M
Investing Cash Flow	4.95M	-49.51K	-192.31K	-1.14M	-2.21M	-444.99K	-1.56M	71.00K	-1.46M	-112.00K	-242.00K	138.00K	-349.00K	-955.00K	-578.00K
Financing Cash Flow	177.37K	15.27M	-358.13K	37.71M	3.06M	22.90M	48.55M	14.85M	41.49M	111.77M	-5.18M	-5.65M	46.77M	-5.13M	37.42M
Capital Expenditure	0	45.39K	196.32K	963.26K	1.49M	400.10K	1.34M	416.00K	1.09M	96.00K	228.00K	92.00K	328.00K	846.00K	546.00K
Free Cash Flow	-4.87M	-3.80M	-7.03M	-9.53M	-18.32M	-18.68M	-22.29M	-26.40M	-42.26M	-27.63M	-30.10M	-37.20M	-12.80M	-20.40M	-33.97M
Dividends Paid	-	1.00M	-	770.64K	-	-	-	0	0	0	0	0	0	0	0
FCF to OCF	100.00%	101.21%	102.87%	111.25%	108.89%	102.19%	106.39%	101.60%	102.65%	100.35%	100.76%	100.25%	102.63%	104.33%	101.63%
Dividend Paid to FCF	-	-26.31%	-	-8.09%	-	-	-	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Earnings

Report Date	Sep 4, 2019	Oct 25, 2019	Mar 17, 2020	Apr 30, 2020	Sep 4, 2020	Oct 23, 2020	Mar 18, 2021	May 5, 2021	Sep 8, 2021	Oct 20, 2021	Mar 30, 2022	Apr 7, 2022	Nov 9, 2022	May 17, 2023	Sep 26, 2023	Nov 13, 2023	Apr 24, 2024	Sep 18, 2024	Nov 29, 2024	Apr 2, 2025	Sep 24, 2025	Nov 28, 2025	Apr 28, 2026	Sep 29, 2026
EPS Estimate	0.00	0.00	0.00	0.00	0.00	-0.73	-0.48	-0.50	-0.70	-1.20	-1.19	-1.06	0.00	-0.75	-0.85	0.00	-0.13	-0.51	0.00	-0.73	-0.35	0.00	-0.39	-
EPS Actual	0.00	0.00	0.00	0.00	0.00	0.00	-0.52	-0.52	0.00	0.00	0.00	-0.20	0.00	0.00	0.00	0.00	-0.13	-0.50	0.00	-0.98	-0.13	0.00	0.00	-
Surprise	-	-	-	-	-	100.00%	-7.46%	-4.36%	100.00%	100.00%	100.00%	81.13%	-	100.00%	100.00%	-	1.08%	1.90%	-	-33.86%	63.84%	-	100.00%	-
Timing	-	-	-	-	-	-	Pre-market	After-hours	-	-	-	After-hours	-	-	-	-	-	-	-	-	After-hours	-	-	After-hours

Key Statistics & Ratios

Market Cap1.70B

Enterprise Value1.81B

Trailing P/E0.00

Forward P/E42.37

Price / Sales52.04

Price / Book65.02

EPS-1.24

Book Value-1.99

Revenue (TTM)32.59M

Gross Profit (TTM)32.59M

EBITDA-10.49M

Profit Margin-73.52%

Operating Margin-196.42%

Return on Equity-198.69%

Return on Assets-10.06%

Shares Outstanding50.92M

Shares Float33.88M

Beta0.57

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Strong Buy

Based on 4 analystsTarget 54.80

Strong Buy
3
Hold
1

Ownership Breakdown

Institutions: 11.95%
Insiders: 0.00%
Retail / Other: 88.05%

Top Institutional Holders

Johnson & Johnson
5.62M11.07%
Morgan Stanley - Brokerage Accounts
36.27K0.07%
Optiver Holding B.V.
13.50K0.03%
Marshall Wace Asset Management Ltd
9.24K0.02%
Citadel Advisors Llc
6.04K0.01%
UBS Group AG
5.56K0.01%
BNP Paribas Arbitrage, SA
3.56K0.01%
Rhumbline Advisers
2.28K0.00%
Royal Bank of Canada
1.82K0.00%
GAMMA Investing LLC
9850.00%
Advisor Group Holdings, Inc.
5000.00%
Wells Fargo & Co
2000.00%
Stone House Investment Management, LLC
760.00%
NATIONAL BANK OF CANADA /FI/
130.00%
Tower Research Capital LLC
10.00%
Citigroup Inc
10.00%
EverSource Wealth Advisors, LLC
00.00%

Top Fund Holders

Fidelity Nasdaq Composite Index
4.49K0.01%
ActivePassive International Equity ETF
1.65K0.00%
Steward Values Enhanced International I
1.05K0.00%